Related Experiment Videos
Intal (sodium cromoglycate) therapy in ulcerative colitis
Acta Allergologica
|January 1, 1977
Summary
Intal, administered rectally, effectively treated ulcerative colitis, achieving remission in 97% of patients within two weeks. Long-term oral SCG therapy maintained remission in 93% of patients over 2-3 years.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Ulcerative colitis is a chronic inflammatory bowel disease.
- Effective treatment options for active ulcerative colitis are crucial.
Purpose of the Study:
- To evaluate the efficacy of intrarectal Intal in treating active ulcerative colitis.
- To assess the long-term remission rates using oral SCG as maintenance therapy.
Main Methods:
- 39 patients with active ulcerative colitis received intrarectal Intal (200 mg daily) for 15 days.
- Maintenance therapy involved oral SCG (240 mg daily) for 2-3 years.
Main Results:
- 97% of patients achieved complete remission within 2 weeks of intrarectal Intal treatment.
- 93% of patients remained in remission during 2-3 years of oral SCG maintenance therapy.
Conclusions:
- Intrarectal Intal is a highly effective short-term treatment for active ulcerative colitis.
- Oral SCG provides durable long-term remission maintenance for ulcerative colitis patients.